About Pemphigus Vulgaris
Pemphigus vulgaris is a potentially life-threatening autoimmune blistering disorder characterised by circulating IgG autoantibodies directed against desmoglein 3 and, in cutaneous disease, desmoglein 1 — desmosomal cadherins essential for keratinocyte adhesion. Loss of epidermal and mucosal cohesion results in suprabasal acantholysis and flaccid blisters that rupture easily, leaving painful, slow-healing erosions predominantly on mucous membranes and the skin. Without immunosuppressive treatment the condition is chronic and progressive; historically fatal, it now carries significant morbidity from both the disease and its treatments.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Pemphigus Vulgaris trials.
Trials typically require serological confirmation with anti-desmoglein 3 (and/or anti-desmoglein 1) ELISA titres at screening — ensure recent antibody levels are documented within the protocol-specified timeframe.
Disease severity grading using the Pemphigus Disease Area Index (PDAI) is the standard outcome measure; understand your baseline PDAI score as minimum severity thresholds are common eligibility criteria.
Prior rituximab use and timing since last infusion is frequently an exclusion criterion or stratification factor; provide a complete biologic treatment history with infusion dates.
Patient Resources
Find recruiting Pemphigus Vulgaris trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Pemphigus Vulgaris. Updated daily.